Skip to main content
Erschienen in: Der Ophthalmologe 2/2014

01.02.2014 | Leitthema

Pharmakokinetik am vorderen Augenabschnitt

verfasst von: Dr. K. Bell, N. Pfeiffer, F.H. Grus

Erschienen in: Die Ophthalmologie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Pharmakokinetik des vorderen Augenabschnittes umfasst die Applikation, Resorption, Bioverfügbarkeit, Metabolisierung und auch die Elimination vor allem topisch applizierter Medikamente. Dabei muss neben der Überwindung der natürlichen Barrieren in Form von Tränenfilm, Kornea, Konjunktiva und Sklera auch auf die korrekte Applikationstechnik geachtet werden. Es gibt verschiedene, meist noch sich in der experimentellen Phase befindliche Ansätze, um eine längere Verweildauer des Medikamentes an der Augenoberfläche zu gewährleisten und eine einfachere Applikation zu erreichen. Weiterhin gibt es viele Bestrebungen, neuere Konservierungsmittel zu verwenden, mit dem Ziel, weniger toxische Nebenwirkungen zu erzeugen.
Literatur
1.
Zurück zum Zitat Ahmed I, Patton TF (1987) Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int J Pharm 38:9–21CrossRef Ahmed I, Patton TF (1987) Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int J Pharm 38:9–21CrossRef
2.
Zurück zum Zitat Baeyens V, Kaltsatos V, Boisrame B et al (1998) Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Release 52:215–220CrossRefPubMed Baeyens V, Kaltsatos V, Boisrame B et al (1998) Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Release 52:215–220CrossRefPubMed
3.
Zurück zum Zitat Baudouin C (2005) Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5:459–463CrossRefPubMed Baudouin C (2005) Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5:459–463CrossRefPubMed
4.
Zurück zum Zitat Brubaker RF (1991) Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci 32:3145–3166PubMed Brubaker RF (1991) Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci 32:3145–3166PubMed
5.
Zurück zum Zitat Davies NM, Farr SJ, Hadgraft J et al (1991) Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res 8:1039–1043CrossRefPubMed Davies NM, Farr SJ, Hadgraft J et al (1991) Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res 8:1039–1043CrossRefPubMed
6.
Zurück zum Zitat Day DG, Walters TR, Schwartz GF et al (2013) Bimatoprost 0.03 % preservative-free ophthalmic solution versus bimatoprost 0.03 % ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol 97:989–993CrossRefPubMedCentralPubMed Day DG, Walters TR, Schwartz GF et al (2013) Bimatoprost 0.03 % preservative-free ophthalmic solution versus bimatoprost 0.03 % ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol 97:989–993CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Duvvuri S, Majumdar S, Mitra AK (2004) Role of metabolism in ocular drug delivery. Curr Drug Metab 5:507–515CrossRefPubMed Duvvuri S, Majumdar S, Mitra AK (2004) Role of metabolism in ocular drug delivery. Curr Drug Metab 5:507–515CrossRefPubMed
8.
Zurück zum Zitat Fukuda M, Shibata S, Shibata N et al (2013) Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations. Clin Ophthalmol 7:515–520CrossRefPubMedCentralPubMed Fukuda M, Shibata S, Shibata N et al (2013) Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations. Clin Ophthalmol 7:515–520CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Gaudana R, Jwala J, Boddu SH et al (2009) Recent perspectives in ocular drug delivery. Pharm Res 26:1197–1216CrossRefPubMed Gaudana R, Jwala J, Boddu SH et al (2009) Recent perspectives in ocular drug delivery. Pharm Res 26:1197–1216CrossRefPubMed
10.
Zurück zum Zitat Gebhardt BM, Kaufman HE (1995) Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocul Pharmacol Ther 11:319–327CrossRefPubMed Gebhardt BM, Kaufman HE (1995) Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocul Pharmacol Ther 11:319–327CrossRefPubMed
11.
Zurück zum Zitat Grass GM, Robinson JR (1988) Mechanisms of corneal drug penetration. II: ultrastructural analysis of potential pathways for drug movement. J Pharm Sci 77:15–23CrossRefPubMed Grass GM, Robinson JR (1988) Mechanisms of corneal drug penetration. II: ultrastructural analysis of potential pathways for drug movement. J Pharm Sci 77:15–23CrossRefPubMed
12.
Zurück zum Zitat Gulsen D, Chauhan A (2004) Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 45:2342–2347CrossRefPubMed Gulsen D, Chauhan A (2004) Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 45:2342–2347CrossRefPubMed
13.
Zurück zum Zitat Gurtler F, Kaltsatos V, Boisrame B et al (1995) Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res 12:1791–1795CrossRefPubMed Gurtler F, Kaltsatos V, Boisrame B et al (1995) Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res 12:1791–1795CrossRefPubMed
14.
Zurück zum Zitat Hamalainen KM, Kananen K, Auriola S et al (1997) Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 38:627–634PubMed Hamalainen KM, Kananen K, Auriola S et al (1997) Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 38:627–634PubMed
15.
Zurück zum Zitat Hatanaka T, Haramura M, Fei YJ et al (2004) Transport of amino acid-based prodrugs by the Na+- and Cl(−) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138–1147CrossRefPubMed Hatanaka T, Haramura M, Fei YJ et al (2004) Transport of amino acid-based prodrugs by the Na+- and Cl(−) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138–1147CrossRefPubMed
16.
Zurück zum Zitat Hiraoka T, Yamamoto T, Okamoto F et al (2012) Time course of changes in ocular wavefront aberration after administration of eye ointment. Eye (Lond) 26:1310–1317 Hiraoka T, Yamamoto T, Okamoto F et al (2012) Time course of changes in ocular wavefront aberration after administration of eye ointment. Eye (Lond) 26:1310–1317
17.
Zurück zum Zitat Huang AJ, Tseng SC, Kenyon KR (1989) Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci 30:684–689PubMed Huang AJ, Tseng SC, Kenyon KR (1989) Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci 30:684–689PubMed
18.
Zurück zum Zitat Kao KD, Lu DW, Chiang CH et al (1990) Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor. J Ocul Pharmacol 6:313–320CrossRefPubMed Kao KD, Lu DW, Chiang CH et al (1990) Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor. J Ocul Pharmacol 6:313–320CrossRefPubMed
19.
Zurück zum Zitat Kaye GI, Sibley RC, Hoefle FB (1973) Recent studies on the nature and function of the corneal endothelial barrier. Exp Eye Res 15:585–613CrossRefPubMed Kaye GI, Sibley RC, Hoefle FB (1973) Recent studies on the nature and function of the corneal endothelial barrier. Exp Eye Res 15:585–613CrossRefPubMed
20.
Zurück zum Zitat Lin HR, Sung KC (2000) Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 69:379–388CrossRefPubMed Lin HR, Sung KC (2000) Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 69:379–388CrossRefPubMed
21.
Zurück zum Zitat Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5:449–455CrossRefPubMed Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5:449–455CrossRefPubMed
22.
Zurück zum Zitat Maul EA, Friedman DS, Quigley HA et al (2012) Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial. Br J Ophthalmol 96:250–253CrossRefPubMed Maul EA, Friedman DS, Quigley HA et al (2012) Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial. Br J Ophthalmol 96:250–253CrossRefPubMed
23.
Zurück zum Zitat Meseguer G, Buri P, Plazonnet B et al (1996) Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 12:481–488CrossRefPubMed Meseguer G, Buri P, Plazonnet B et al (1996) Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 12:481–488CrossRefPubMed
24.
Zurück zum Zitat Moya-Ortega MD, Alves TF, Alvarez-Lorenzo C et al (2013) Dexamethasone eye drops containing gamma-cyclodextrin-based nanogels. Int J Pharm 441:507–515CrossRefPubMed Moya-Ortega MD, Alves TF, Alvarez-Lorenzo C et al (2013) Dexamethasone eye drops containing gamma-cyclodextrin-based nanogels. Int J Pharm 441:507–515CrossRefPubMed
25.
Zurück zum Zitat Mundada AS, Shrikhande BK (2008) Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 33:469–475CrossRefPubMed Mundada AS, Shrikhande BK (2008) Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 33:469–475CrossRefPubMed
26.
Zurück zum Zitat Mundorf T, Wilcox KA, Ousler GW 3rd et al (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20:329–336CrossRefPubMed Mundorf T, Wilcox KA, Ousler GW 3rd et al (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20:329–336CrossRefPubMed
27.
Zurück zum Zitat Noecker R (2001) Effects of common ophthalmic preservatives on ocular health. Adv Ther 18:205–215CrossRefPubMed Noecker R (2001) Effects of common ophthalmic preservatives on ocular health. Adv Ther 18:205–215CrossRefPubMed
28.
Zurück zum Zitat Ohta K, Wiggert B, Taylor AW et al (1999) Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 40:2010–2018PubMed Ohta K, Wiggert B, Taylor AW et al (1999) Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 40:2010–2018PubMed
29.
Zurück zum Zitat Pham XT, Huff JW (1999) Cytotoxicity evaluation of multipurpose contact lens solutions using an in vitro test battery. Clao J 25:28–35PubMed Pham XT, Huff JW (1999) Cytotoxicity evaluation of multipurpose contact lens solutions using an in vitro test battery. Clao J 25:28–35PubMed
30.
Zurück zum Zitat Raviola G (1977) The structural basis of the blood-ocular barriers. Exp Eye Res 25(Suppl):27–63CrossRefPubMed Raviola G (1977) The structural basis of the blood-ocular barriers. Exp Eye Res 25(Suppl):27–63CrossRefPubMed
31.
Zurück zum Zitat Saettone MF, Giannaccini B, Teneggi A et al (1982) Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man. J Pharm Pharmacol 34:464–466CrossRefPubMed Saettone MF, Giannaccini B, Teneggi A et al (1982) Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man. J Pharm Pharmacol 34:464–466CrossRefPubMed
32.
Zurück zum Zitat Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13:144–151CrossRefPubMed Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13:144–151CrossRefPubMed
33.
Zurück zum Zitat Schoenwald RD (1990) Ocular drug delivery. Pharmacokinetic considerations. Clin Pharmacokinet 18:255–269CrossRefPubMed Schoenwald RD (1990) Ocular drug delivery. Pharmacokinetic considerations. Clin Pharmacokinet 18:255–269CrossRefPubMed
34.
Zurück zum Zitat Schrage N, Frentz M, Spoeler F (2012) The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch Clin Exp Ophthalmol 250:1333–1340CrossRefPubMed Schrage N, Frentz M, Spoeler F (2012) The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch Clin Exp Ophthalmol 250:1333–1340CrossRefPubMed
35.
Zurück zum Zitat Shedden A, Laurence J, Tipping R (2001) Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 23:440–450CrossRefPubMed Shedden A, Laurence J, Tipping R (2001) Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 23:440–450CrossRefPubMed
36.
Zurück zum Zitat Shirasaki Y (2008) Molecular design for enhancement of ocular penetration. J Pharm Sci 97:2462–2496CrossRefPubMed Shirasaki Y (2008) Molecular design for enhancement of ocular penetration. J Pharm Sci 97:2462–2496CrossRefPubMed
37.
Zurück zum Zitat Tabuchi N, Hattori M, Shimizu M et al (2012) Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. J Toxicol Sci 37:639–643CrossRefPubMed Tabuchi N, Hattori M, Shimizu M et al (2012) Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. J Toxicol Sci 37:639–643CrossRefPubMed
38.
Zurück zum Zitat Talwar D, Kulkarni A, Azad R et al (2003) Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest Ophthalmol Vis Sci 44:505–509CrossRefPubMed Talwar D, Kulkarni A, Azad R et al (2003) Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. Invest Ophthalmol Vis Sci 44:505–509CrossRefPubMed
39.
Zurück zum Zitat Tonjum AM (1974) Permeability of horseradish peroxidase in the rabbit corneal epithelium. Acta Ophthalmol (Copenh) 52:650–658 Tonjum AM (1974) Permeability of horseradish peroxidase in the rabbit corneal epithelium. Acta Ophthalmol (Copenh) 52:650–658
40.
Zurück zum Zitat Urtti A, Pipkin JD, Rork G et al (1990) Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits. Int J Pharm 61:241–249CrossRef Urtti A, Pipkin JD, Rork G et al (1990) Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits. Int J Pharm 61:241–249CrossRef
41.
Zurück zum Zitat Yamada Y, Takayanagi R, Tsuchiya K et al (2001) Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 17:235–248CrossRefPubMed Yamada Y, Takayanagi R, Tsuchiya K et al (2001) Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 17:235–248CrossRefPubMed
42.
Zurück zum Zitat Zimmerman TJ, Sharir M, Nardin GF et al (1992) Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol 114:1–7PubMed Zimmerman TJ, Sharir M, Nardin GF et al (1992) Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol 114:1–7PubMed
Metadaten
Titel
Pharmakokinetik am vorderen Augenabschnitt
verfasst von
Dr. K. Bell
N. Pfeiffer
F.H. Grus
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Ophthalmologie / Ausgabe 2/2014
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-013-2931-x

Weitere Artikel der Ausgabe 2/2014

Der Ophthalmologe 2/2014 Zur Ausgabe

Update Ophthalmologie

Kinderaugenheilkunde

Originalien

Maurerschnüre

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.